PI3K Inhibitors For Hematology Indications Need Randomized Data, FDA Panel Says

 
• By Sue Sutter
Crystal ball
ODAC members are not fortune-tellers, but FDA asked them to set development expectations for future PI3K inhibitors based on past experience with the class. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers